GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (FRA:ISI) » Definitions » Net Margin %

Ionis Pharmaceuticals (FRA:ISI) Net Margin % : -104.98% (As of Sep. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Ionis Pharmaceuticals's Net Income for the three months ended in Sep. 2024 was €-126.6 Mil. Ionis Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was €120.6 Mil. Therefore, Ionis Pharmaceuticals's net margin for the quarter that ended in Sep. 2024 was -104.98%.

The historical rank and industry rank for Ionis Pharmaceuticals's Net Margin % or its related term are showing as below:

FRA:ISI' s Net Margin % Range Over the Past 10 Years
Min: -60.92   Med: -17.2   Max: 45.65
Current: -44.68


FRA:ISI's Net Margin % is ranked better than
61.99% of 1013 companies
in the Biotechnology industry
Industry Median: -140.3 vs FRA:ISI: -44.68

Ionis Pharmaceuticals Net Margin % Historical Data

The historical data trend for Ionis Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Net Margin % Chart

Ionis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.78 -60.92 -3.53 -45.92 -46.50

Ionis Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -102.22 -2.85 -119.50 -29.42 -104.98

Competitive Comparison of Ionis Pharmaceuticals's Net Margin %

For the Biotechnology subindustry, Ionis Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Net Margin % falls into.



Ionis Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Ionis Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-335.884/722.272
=-46.50 %

Ionis Pharmaceuticals's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-126.572/120.566
=-104.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ionis Pharmaceuticals  (FRA:ISI) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Ionis Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ionis Pharmaceuticals Business Description

Traded in Other Exchanges
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.

Ionis Pharmaceuticals Headlines

No Headlines